DUR Board Meeting Minutes Draft

Name of Meeting Drug Utilization Review Board

Date of Meeting Thursday, November 4, 2004

Length of Meeting 2:15 PM – 4:03 PM

Location of Meeting DMAS Board Room 13th Floor

Members Present:
Geneva Briggs, PharmD
Jason Lyman, MD
Elaine Ferrary, MS, RN/CFNP
Jennifer Edwards, PharmD
Jane Settle, CNP

(Not present: Bill Rock, PharmD, Kelly Goode, PharmD, Thomas Moffatt, MD, Sandra Dawson, R.Ph, Robert Friedel, MD, Matthew Goodman, MD, Catherine Kelso, MD, Mark Johnson, PharmD)

DMAS Attendees:
Javier Menendez, R.Ph
Rachel Cain, PharmD
Tyrone Wall, Compliance Specialist

Contractor: Donna Johnson, R.Ph, First Health Services Corporation
Debbie Moody, R.Ph, First Health Services Corporation

Visitors:
Kevin Pauley: Forest Labs
John Deegan
Carl Tullio: Pfizer Inc.
Wayne Mullins: Forest Labs

Chair Geneva Briggs called the meeting to order.

The action on the minutes from meetings on May 6, 2004 and August 12, 2004 was deferred to next meeting due to lack of quorum.

New Drugs

The DUR Board reviewed a list of criteria and standards for: Cymbalta®, Symbyax®, Ketek®, and Spiriva®, however the committee was unable to approve the criteria due to a lack of quorum.

Antipsychotic Criteria

Typical Antipsychotics Table 1 containing first generation Typical Antipsychotics was reviewed and will be revisited at the next meeting.

Atypical Antipsychotics- Table 2 containing second generation Antipsychotics was discussed. The committee felt that hyperlipidemia should be added as an adverse effect for Risperidone.

Beer's Criteria Review Report

One thousand medication profiles were generated for all Medicaid enrollees 65 years and older who were expected to meet any of the Beers criteria. Letters were sent to prescribers for 466 Medicaid enrollees. There were 731 criteria interventions in a total of 533 letters sent to prescribers whose patients are receiving medication or dosage that are potentially inappropriate for them. Many of the letters contained more than one criteria intervention. Furthermore, many of the enrollees had letters sent to more than one prescriber. Out of the 533 letters sent out, 225 responses were received. The preliminary response report had a 42% response rate.

ProDUR Reports

The committee reviewed the comparison of early refill claims and the early refill claims analysis. After tracking several recipients and much discussion on their refill history all agreed that the early refill edit is appropriate.

RetroDUR Report

The committee reviewed the RetroDUR Review Reports from February 2004 through August 2004, the RetroDUR Profile Intervention Summary for profile cycle year 2004, and the RetroDUR Letter Response Report By Response Code for profile period February 2004 through July 2004.

Future RetroDUR Review Topics

1. QT prolongation
2. PG-D or X criteria is available
3. CURE- Plavix and aspirin
4. Congestive heart failure patients not on Angiotensin-Converting-Enzyme-Inhibitors (ACES) and Angiotensin Receptor Antagonist (ABRS)
5. Diabetics not on Angiotensin-Converting-Enzyme-Inhibitors (ACES)
6. Diabetics not on statins

The committee asked Donna Johnson from First Health Services to choose one topic from the proposed review topics and prepare the information for discussion at the next meeting.

Selection of Tentative Meeting Dates for 2005

February 10, May 12, August 11, November 10

Other Business

Geneva Briggs requested a review of the DUR Board by-laws be added to the agenda of the February 10, 2005 DUR Board Meeting. Also she questioned whether the quorum or percentage of membership might be redefined at the next meeting.

Adjournment 4:03 PM